Date: 2017-08-10
Type of
information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: Diamyd Medical (Sweden)
Product: Diamyd®
Action
mechanism:
- protein. Diamyd® is an antigen-based diabetes therapy under development to prevent, delay, or stop the autoimmune attack on beta cells in type 1 diabetes and other forms of autoimmune diabetes, thereby preserving the body's capacity to regulate blood sugar. The active substance in the Diamyd® diabetes vaccine is glutamic acid decarboxylase isoform 65kDa (GAD). GAD is one of the most important targets when the immune system attacks the beta cells in autoimmune diabetes. Accordingly, GAD is an autoantigen. Treatment using Diamyd® is intended to stop the autoimmune attack against the beta cells by inducing tolerance to GAD.
Disease: type 1 diabetes
Therapeutic
area: Autoimmune diseases - Metabolic diseases
Country:
Trial
details:
Latest
news:
- • On August 10, 2017, Diamyd Medical announced a collaboration with Cardiff University on a new study with the diabetes vaccine Diamyd®. The aim of the study is to optimize methods based on ultrasound guided lymph node biopsies for monitoring the cellular immune response to immunotherapy. The study is financed by Cardiff University while Diamyd Medical is supplying the study drug.
Diamyd® will be administered intradermally in 12 patients with type 1 diabetes and the immune response will be monitored directly in the lymphatic fluid through ultrasound guided lymph node biopsies. Intradermal administration (via the skin) like direct intra-lymph-node administration of autoantigens, such as GAD, is believed to significantly enhance antigen specific tolerization, as compared to subcutaneous administration. Chief Investigator is Professor Colin Dayan and Principal Investigator is Dr. Danijela Tatovic.
Is
general: Yes
